Inhibitors | Comment | Organism | Structure |
---|---|---|---|
aurintricarboxylic acid | - |
Severe acute respiratory syndrome-related coronavirus | |
additional information | the high sequence conservation between SARS-CoV RNA-dependent RNA polymerase (RdRp) and SARS-CoV-2 RNA polymerase makes it very likely that any potent agents developed for the SARS-CoV RdRp will exhibit equal potency and efficacy on the SARS-CoV-2 enzyme | Severe acute respiratory syndrome coronavirus 2 | |
additional information | the high sequence conservation between SARS-CoV RNA-dependent RNA polymerase (RdRp) and SARS-CoV-2 RNA polymerase makes it very likely that any potent agents developed for the SARS-CoV RdRp will exhibit equal potency and efficacy on the SARS-CoV-2 enzyme | Severe acute respiratory syndrome-related coronavirus | |
remdesivir | - |
Severe acute respiratory syndrome-related coronavirus | |
ribavirin | - |
Severe acute respiratory syndrome-related coronavirus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Severe acute respiratory syndrome coronavirus 2 | MN908947 | i.e. SARS-CoV-2 | - |
Severe acute respiratory syndrome-related coronavirus | P0C6X7 | human, i.e. SARS-CoV | - |
Synonyms | Comment | Organism |
---|---|---|
RDRP | - |
Severe acute respiratory syndrome-related coronavirus |
RDRP | - |
Severe acute respiratory syndrome coronavirus 2 |
RNA-dependent RNA polymerase | - |
Severe acute respiratory syndrome coronavirus 2 |
General Information | Comment | Organism |
---|---|---|
drug target | the high sequence conservation between SARS-CoV RNA-dependent RNA polymerase (RdRp) and SARS-CoV-2 RNA polymerase makes it very likely that any potent agents developed for the SARS-CoV RdRp will exhibit equal potency and efficacy on the SARS-CoV-2 enzyme | Severe acute respiratory syndrome-related coronavirus |
drug target | the high sequence conservation between SARS-CoV RNA-dependent RNA polymerase (RdRp) and SARS-CoV-2 RNA polymerase makes it very likely that any potent agents developed for the SARS-CoV RdRp will exhibit equal potency and efficacy on the SARS-CoV-2 enzyme | Severe acute respiratory syndrome coronavirus 2 |